United States · Platforms & data · MarketWatch
The FDA declined to approve one of biotech’s most closely watched cancer drugs
Detailed summary
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketwatch.com)




